NasdaqCM:MDXHBiotechs
MDxHealth (MDXH) Q1 Loss Near US$8.9 Million Reinforces Bearish Profitability Concerns
MDxHealth (NasdaqCM:MDXH) opened Q1 2026 with revenue of US$27.4 million and a basic EPS loss of US$0.17, alongside trailing 12 month revenue of US$111.0 million and a cumulative net loss of US$33.2 million that keeps the focus firmly on profitability. Over the last year, the company has seen revenue move from US$24.7 million in Q4 2024 to US$27.4 million in Q1 2026, while quarterly EPS has stayed in a tight range between a loss of US$0.14 and US$0.19, highlighting a situation where top line...